Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214787 | 1.00 | DRD2 (0.39) | DRD2SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL4191008 | 1.00 | DRD2 (0.39) | DRD2SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL19261800 | 1.00 | DRD2 (0.39) | DRD2SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL14124614 | 0.83 | DRD2 (0.40) | DRD2SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL22917996 | 0.83 | SLC6A3 (0.48) | DRD2SLC6A3SLC6A4 | |
| SCHEMBL4874867 | 0.83 | SLC6A3 (0.48) | DRD2SLC6A3SLC6A4 | |
| SCHEMBL4180226 | 0.83 | DRD2 (0.40) | DRD2SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13698145 | 0.83 | SLC6A3 (0.48) | DRD2SLC6A3SLC6A4 | |
| SCHEMBL14255652 | 0.83 | SLC6A3 (0.48) | DRD2SLC6A3SLC6A4 | |
| SCHEMBL8208823 | 0.83 | SLC6A3 (0.48) | DRD2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9737506-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9205074-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-8877798-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | disclosed |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | DRD2 35/4885SLC6A3 92/4885SLC6A4 221/4885 |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1D, HTR1B | DRD2 29/4885SLC6A3 112/4885SLC6A4 261/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | DRD2 35/4885SLC6A3 92/4885SLC6A4 221/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | DRD2 35/4885SLC6A3 92/4885SLC6A4 221/4885 |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | DRD2 35/4885SLC6A3 92/4885SLC6A4 221/4885 |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | DRD2 35/4885SLC6A3 92/4885SLC6A4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.